Juvenile myelomonocytic leukemia (JMML) is a rare hematologic malignancy in childhood and accounts for less than 3% of all childhood hematologic malignancies.1 The role of hyperactive RAS in JMML is underlined by the fact that approximately 80% of JMML develop due to gain-of-function mutations in NRAS, KRAS, PTPN11 and SOS1 or homozygous loss-of-function mutations in NF1 or c-CBL.2–4 These genes are all components of the RAS/ERK signaling network, implicating deregulation of this signaling pathway in JMML pathogenesis. Therefore, it may be speculated that JMML lacking known mutations of genes playing a role in RAS signaling may carry other mutations, which result in activation of this pathway. Recently, germline mi-RNA gene variations were proposed to affect the expression levels of tumor suppressor or oncogenes and, thereby, familial/hereditary cancer risk.5 The let-7 mi-RNA family targets many important genes including cell cycle regulators such as CDC25A and CDK6, a number of early embryonic genes including HMGA2, Mlin-41 and IMP-1 and promoters of growth including RAS and C-MYC. In Caenorhabditis elegans let-7 mutant seam cells fail to exit the cell cycle and to terminally differentiate, thus demonstrating continuous proliferation, a hallmark of cancer.6 Human RAS expression was also shown to be regulated by let-7.7 Evidence of a role of let-7 in cancer came from the observation that lung tumor tissues display significantly reduced let-7 levels and significantly increased RAS protein levels relative to normal lung tissue.8 Recently, an SNP (rs61764370) in a let-7 complementary site in the KRAS 3’ UTR, which leads to KRAS overexpression, was shown to increase non-small cell lung cancer risk.9 It is still unknown whether alterations of the let-7 binding site in target genes or if mutations of let-7 mi-RNAs play a role in the development and progression of JMML. To address this question, we sequenced the 3’UTR of N-RAS and K-RAS in bone marrow cells from 10 JMML patients who had no other known RAS pathway mutations. The let-7 complementary sites LCS1-LCS9 in the 3′ UTR of NRAS and the complementary sites LCS1-LCS8 of KRAS were amplified and PCR products were directly sequenced.7 No sequence alterations were found in the 3′ UTR of NRAS or KRAS. However, in KRAS, the SNP rs61764370 T>G in the LCS6 was observed in one case. So far, only a few studies have investigated whether germline mutations in genomic mi-RNA sequences predispose to development of certain types of cancer or other diseases.10,11 Recently, a germline mutation in mature miR-125a was found to be highly associated with breast cancer tumorigenesis, suggesting that miR-125a is likely to function as a tumor suppressor gene in human cancer.12 Sequencing of let-7a-1 (MI0000060) as well as the neighboring let-7f-1 (MI0000067) genomic sequences in the 10 JMML cases did not identify any sequence alterations in these genomic regions.
In summary, we found no evidence that mutations in let-7 or in binding sites of let-7 mRNA targets lead to an upregulation of RAS genes in JMML. Yet, we cannot rule out that other mi-RNAs known to bind to NRAS- or KRAS-UTR or other let-7 family miRNAs may play a role in the development of JMML.
References
- Hasle H, Wadsworth LD, Massing BG, McBride M, Schultz KR. A population-based study of childhood myelodysplastic syndrome in British Columbia, Canada. Br J Haematol. 1999; 106(4):1027-32. Google Scholar
- Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer. 2007; 7(4):295-308. Google Scholar
- Flotho C, Kratz C, Niemeyer CM. Targeting RAS signaling pathways in juvenile myelomonocytic leukemia. Curr Drug Targets. 2007; 8(6):715-25. Google Scholar
- Loh ML, Sakai DS, Flotho C, Kang M, Fliegauf M, Archambeault S. Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood. 2009; 114(9):1859-63. Google Scholar
- Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006; 6(11):857-66. Google Scholar
- Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature. 2000; 403(6772):901-6. Google Scholar
- Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A. RAS is regulated by the let-7 microRNA family. Cell. 2005; 120(5):635-47. Google Scholar
- Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 2004; 64(11):3753-6. Google Scholar
- Chin LJ, Ratner E, Leng S, Zhai R, Nallur S, Babar I. A SNP in a let-7 microRNA complementary site in the KRAS 3′ untranslated region increases non-small cell lung cancer risk. Cancer Res. 2008; 68(20):8535-40. Google Scholar
- Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, Coetzee GA. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell. 2006; 9(6):435-43. Google Scholar
- Shen J, DiCioccio R, Odunsi K, Lele S, Zhao H. Novel genetic variants in miR-191 gene and familial ovarian cancer. BMC Cancer. 2010; 10(1):47. Google Scholar
- Li W, Duan R, Kooy F, Sherman SL, Zhou W, Jin P. Germline mutation of microRNA-125a is associated with breast cancer. J Med Genet. 2009; 46(5):358-60. Google Scholar